SLC2A10 was expressed at lower levels than in normal tissue in colorectal cancer, head and neck cancer, liver cancer, and melanoma but expressed at higher levels than in normal tissue in bladder cancer, brain and central nervous system cancer, breast cancer, kidney cancer, lymphoma and sarcoma (Fig. 2A). Here, SLC2A10 is linked to kidney cancer.